SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 4,000 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $5.70, for a total transaction of $22,800.00. Following the completion of the transaction, the insider owned 610,887 shares of the company’s stock, valued at $3,482,055.90. This trade represents a 0.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81.
• On Monday, April 20th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total value of $3,167.68.

SOPHiA GENETICS Stock Performance

SOPH opened at $5.68 on Wednesday. The business’s 50-day moving average price is $5.19 and its two-hundred day moving average price is $5.00. SOPHiA GENETICS SA has a 1 year low of $2.92 and a 1 year high of $6.30. The company has a market capitalization of $476.50 million, a price-to-earnings ratio of -10.92 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SOPH. BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.50.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently modified their holdings of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Federated Hermes Inc. increased its position in shares of SOPHiA GENETICS by 16.4% during the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after purchasing an additional 31,000 shares during the last quarter. Akre Capital Management LLC increased its position in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $49,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.